GCG and type 2 diabetes mellitus: The evidence from cardiovascular outcome trials on the benefits of GLP-1 (glucagon-like peptide 1) agonists and SGLT 2 (sodium–glucose cotransporter 2) inhibitors has significantly modified treatment strategies for individuals with type 2 diabetes (T2DM) [1,2,3,4].